Trial reportJournal of hypertension2022
Effect of dihydropyridine calcium channel blockers on blood pressure variability in the SPRINT trial: a treatment effects approach.
Trial report in Journal of hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Anti-hypertensive Drug Classes and Risk of New-Onset Atrial Fibrillation in Healthy Older Adults: A Post Hoc Analysis of ASPREE Trial.Drugs & aging · 2025Trial
- Comparison of visit-to-visit blood pressure variability and time in target range in predicting risk for cognitive outcomes in the SPRINT trial.Journal of Alzheimer's disease : JAD · 2025Trial
- 24-Hour Blood Pressure Variability Via Ambulatory Monitoring and Risk for Probable Dementia in the SPRINT Trial.The journal of prevention of Alzheimer's disease · 2024Trial
- Visit-to-Visit Systolic Blood Pressure Variability Predicts Long-Term Cardiovascular Events After Coronary Artery Bypass Grafting.Journal of clinical hypertension (Greenwich, Conn.) · 2026Observational
- Asian expert consensus on high-quality hypertension management.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Interactions between blood pressure variability, cerebral autoregulation, and covert cerebral small vessel disease in relation to cognitive performance in community-dwelling older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Visit-to-visit blood pressure variability and dementia risk after considering antihypertensive treatment: real-world data from the Japanese National Health Insurance.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Differential Effects of Antihypertensive Drug Classes on Home and Office Blood Pressure Variability.International journal of hypertension · 2026Article
- Research progress on the correlation between blood pressure variability and hypertensive microvascular disease.Frontiers in cardiovascular medicine · 2026Review
- Long-Term Blood Pressure Variability and Physical Performance in Older Adults.Journal of clinical hypertension (Greenwich, Conn.) · 2025Observational
- Blood pressure variability: a review.Journal of hypertension · 2025Review
- The effect of visit-to-visit blood pressure variability on cognitive function: state-of the-art.Cerebral circulation - cognition and behavior · 2025Article
- Effect of the DASH diet on the sodium-chloride cotransporter and aquaporin-2 in urinary extracellular vesicles.American journal of physiology. Renal physiology · 2024Article
- Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial.European heart journal · 2024Article
- Article
- Blood Pressure Variability and Plasma Alzheimer's Disease Biomarkers in the SPRINT Trial.Journal of Alzheimer's disease : JAD · 2024Article
- Changes in beat-to-beat blood pressure and pulse rate variability following stroke.Scientific reports · 2023Article
- Blood Pressure Variability as a Risk Factor for Cardiovascular Disease: Which Antihypertensive Agents Are More Effective?Journal of clinical medicine · 2023Article
- Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.Journal of the American Heart Association · 2023Article
- Variation in Mean Arterial Pressure Increases Falls Risk in Elderly Physically Frail and Prefrail Individuals Treated With Antihypertensive Medication.Hypertension (Dallas, Tex. : 1979) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveIncreased visit-to-visit blood pressure variability (vvBPV) has negative effects on multiple organ systems. Prior research has suggested that dihydropyridine calcium channel blockers (CCB) may reduce vvBPV, which we attempted to verify in a high-quality dataset with robust statistical methodology.
methodsWe performed a post hoc analysis of the SPRINT trial and included participants who were on a dihydropyridine CCB either 0 or 100% of follow-up study visits. The primary outcome was vvBPV, defined as residual standard deviation (rSD) of SBP from month 6 until study completion. We estimated the average treatment effect of the treated (ATET) after augmented inverse-probability-weighting (AIPW) matching.
resultsOf the 9361 participants enrolled in SPRINT, we included 5020, of whom 1959 were on a dihydropyridine CCB and 3061 were not; mean age was 67.4 ± 9.2 years, 34.5% were men, 65.9% were white, 49.4% were randomized to intensive blood pressure control, and the rSD was 10.1 ± 4.0 mmHg. Amlodipine represented greater than 95% of dihydropyridine CCB use. After AIPW matching of demographics and other antihypertensive medications, the ATET estimation for participants on a dihydropyridine CCB was an rSD that was 2.05 mmHg lower (95% CI -3.19 to -0.91). We did not find that other antihypertensive medications classes decreased vvBPV, and several increased it.
conclusionIn the SPRINT trial, consistent use of a dihydropyridine CCB was associated with a 2 mmHg reduction in vvBPV. The implication of this hypothesis-generating finding in a high-quality dataset is that future trials to reduce vvBPV could consider using dihydropyridine CCBs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.